A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a ...

Please provide your email address to receive an email when new articles are posted on . Atezolizumab plus bevacizumab appeared well-tolerated and resulted in a 40% objective response rate among ...

Please provide your email address to receive an email when new articles are posted on . “In clinic, we have seen some people experience durable clinical benefit from pembrolizumab, so I was not ...

Malignant peritoneal mesothelioma is a rare disease, with approximately 800 new patients per year in the United States. Its natural history is defined by progression restricted to the peritoneal space ...

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective ...

Mesothelioma is commonly linked to older men, but younger individuals can also be affected, leading to initial confusion and fear. Access to specialized treatment, such as hyperthermic intraperitoneal ...

Over the past 15 or 20 years, a rare form of cancer known as mesothelioma has become increasingly common – affecting as many as 3,000 Americans each year. Additionally, roughly 2,500 ...